Skandinaviska Enskilda Banken AB publ Trims Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

Skandinaviska Enskilda Banken AB publ lowered its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 67.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 189,472 shares of the company’s stock after selling 394,017 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Sana Biotechnology were worth $305,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB acquired a new stake in Sana Biotechnology during the 3rd quarter valued at approximately $29,000. Blue Trust Inc. raised its holdings in shares of Sana Biotechnology by 51.0% during the fourth quarter. Blue Trust Inc. now owns 19,823 shares of the company’s stock worth $32,000 after purchasing an additional 6,694 shares during the last quarter. Ieq Capital LLC acquired a new position in Sana Biotechnology during the fourth quarter valued at $32,000. Stifel Financial Corp purchased a new stake in Sana Biotechnology in the third quarter valued at $43,000. Finally, EP Wealth Advisors LLC acquired a new stake in Sana Biotechnology during the 3rd quarter worth about $45,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Trading Down 5.5 %

NASDAQ SANA opened at $2.77 on Tuesday. The stock has a market capitalization of $618.46 million, a price-to-earnings ratio of -1.98 and a beta of 1.63. The stock has a 50-day moving average of $3.05 and a 200 day moving average of $3.23. Sana Biotechnology, Inc. has a twelve month low of $1.52 and a twelve month high of $10.50.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Thursday, March 20th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Equities analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Insider Buying and Selling at Sana Biotechnology

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. This represents a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 31.10% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on SANA shares. Jefferies Financial Group assumed coverage on Sana Biotechnology in a report on Friday. They issued a “buy” rating and a $7.00 price objective for the company. TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright lifted their target price on shares of Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $12.25.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.